A Study in Benign Prostatic Hyperplasia

Status Completed

Clinical Trial Summary

The purpose of this trial is to evaluate the effect of tadalafil 5 milligrams (mg) daily for 8 weeks compared to placebo on prostatic blood perfusion in men with signs and symptoms of Benign Prostatic Hyperplasia (BPH), measured by resistive index (RI) in the prostate transition zone.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01152190
Study type	Interventional
Source	Eli Lilly and Company
Contact
Status	Completed
Phase	Phase 3
Start date	September 2010
Completion date	July 2012

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04807296` - Thulium Fiber Laser Enucleation of the Prostate (TFLEP) vs HoLEP With Moses Technology (m-HoLEP)	N/A
Recruiting	`NCT05574244` - Comparison of Functional Outcomes of Ejaculation-preserving Partial Trans Urethral Resection of the Prostate With Complete Trans Urethral Resection of the Prostate for Benign Prostatic Obstruction	N/A
Recruiting	`NCT04288427` - 5-Alpha Reductase 2 as a Marker of Resistance to 5ARI Therapy	N/A
Not yet recruiting	`NCT04245566` - Prostatic Artery Embolization vs. Pharmacotherapy for LUTS/BPH	Phase 3
Completed	`NCT02509975` - Safety and Efficacy of OCL 503 in Prostate Artery Embolization	N/A
Withdrawn	`NCT01967251` - Efficacy, Safety and Dose-response of Udenafil in Patients With Benign Prostatic Hyperplasia and Erectile Dysfunction	Phase 2
Completed	`NCT03246880` - Clinical Trial To Evaluate the Efficacy and Safety of CKD-397 in Benign Prostatic Hyperplasia Patients	Phase 3
Completed	`NCT02206243` - Embozene® Microspheres for Prostatic Arterial Embolization in Patients With Symptomatic Benign Prostatic Hyperplasia
Completed	`NCT02283684` - GreenLight Laser Photoselective Vaporization of the Prostate vs Bipolar Transurethral Vaporization of the Prostate; RCT	Phase 4
Completed	`NCT01454349` - Study of PRX302 for Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia (BPH)	Phase 1/Phase 2
Completed	`NCT01438775` - Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)	Phase 3
Completed	`NCT01139762` - A Study of Tadalafil Use With Finasteride in Men With Enlarged Prostates and Urinary Symptoms	Phase 3
Active, not recruiting	`NCT00400894` - Annexin A3 (ANXA3) as Protein-Based Marker for Non-Invasive Molecular Diagnostics of Prostate Carcinoma	N/A
Completed	`NCT00224133` - The Evaluation of the Safety of a New Drug for Benign Prostatic Hyperplasia Used for 9 Months	Phase 3
Unknown status	`NCT00381108` - Study of the Effects of Pomegranate Tablets on Enlarged Prostates	Phase 1
Completed	`NCT00701779` - Dutasteride and Flex Dose of Tamsulosin on as Needed Basis, to Treat Benign Prostatic Hyperplasia	Phase 4
Terminated	`NCT02962674` - To Evaluate the Safety and Performance of the ProstaCare Water Electrolysis System in Relieving Symptoms of BPH.	N/A
Active, not recruiting	`NCT05415748` - Deprescribing Tamsulosin in Older Men	Phase 4
Recruiting	`NCT04853914` - Evaluation of the Safety of the Treatment of Benign Prostatic Hyperplasia by High Intensity Focused Ultrasound.	N/A
Completed	`NCT04831476` - Α Prospective Observational Study for the Evaluation of Disease Control and Quality of Life in Patients With Benign PROStatic hyPERplasia Under Fixed Dose combΙnaTion Treatment With Dutasteride and Tamsulosin . PROSPERITY Group of Studies (I&II)